Membranous Nephropathy (MN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Membranous Nephropathy (MN) Market Outlook
Thelansis’s “Membranous Nephropathy
(MN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Membranous Nephropathy (MN)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Membranous Nephropathy (MN) Overview
Membranous
Nephropathy (MN), also called membranous glomerulopathy, is a type of
glomerular disease resulting in nephrotic syndrome. It is defined by the
presence of significant proteinuria (>3.5 g/day) and the manifestation of
clinical symptoms such as peripheral edema, hypertension, frothy urine, and
thromboembolic events. MN can be classified into primary (75-80%) and secondary
(20-25%) forms. Primary MN is often idiopathic but may be associated with
antibodies against the phospholipase A2 receptor (PLA2R) antigen (70-80%),
neural epidermal growth factor-like 1 (NELL) (15-20%), thrombospondin (1-5%),
neutral endopeptidase (NEP), or exostosin (EXT1/EXT2). Secondary MN is linked
to infections, neoplasms, drugs, heavy metal poisoning, autoimmune diseases, and
other miscellaneous factors. The formation of antigen-antibody complexes
between the glomerular basement membrane and podocytes causes MN. These
complexes, which primarily consist of immunoglobulin IgG4, complement C3, and
C5b-C9 membrane attack complexes (MAC), activate the complement system and
generate proteases, cytokines, and oxidants that result in cellular and tissue
damage, leading to proteinuria.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment